TransThera Sciences

Executive Summary

TransThera Sciences is a clinical-stage biopharmaceutical company based in Nanjing, China, focused on discovering and developing novel small molecule therapeutics for oncology, immunology, and fibrotic diseases. Founded in 2016, the company leverages an integrated discovery platform to identify targets and advance drug candidates with best-in-class or first-in-class potential. Its pipeline includes internally discovered compounds as well as in-licensed assets, targeting areas of high unmet medical need. While specific pipeline details are not publicly disclosed, the company's platform-driven approach positions it to generate multiple clinical candidates. TransThera has raised significant private funding and is advancing its lead programs toward key clinical milestones. The company's progress in a competitive landscape will depend on successful clinical data readouts and strategic partnerships to support further development and potential commercialization.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for lead oncology candidate60% success
• Q1 2027IND filing for a novel immunology asset70% success
• H2 2026Out-licensing or collaboration deal for fibrotic disease program40% success